Article
Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission.
AIDS (London, England) - 4 Jul 2003
Giuliano Marina, Palmisano Lucia, Galluzzo Clementina M, Amici Roberta, Germinario Elena, Okong Pius, Kituuka Praxedes, Mmirro Francis, Magoni Michele, Vella Stefano
Abstract excerpt
Two zidovudine/lamivudine regimens for the prevention of HIV perinatal transmission were studied for the selection of resistance mutations. The M184V mutation was detected one week after delivery in six out of fifty women (12%) who received the regimen prepartum, intrapartum and postpartum, and was no longer present 3 months later. No nucleoside reverse transcriptase inhibitor resistance-associated mutations were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.